Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle
1998

Improving Radioimmunotherapy with a Second Antibody

Sample size: 4 publication Evidence: moderate

Author Information

Author(s): JL Casey, DJ King, RB Pedley, JA Boden, R Boden, LC Chaplin, M Dorning, RHJ Begent

Primary Institution: Cancer Research Campaign Laboratories, Royal Free Hospital School of Medicine

Hypothesis

Can a second antibody improve the therapeutic ratio in radioimmunotherapy by reducing blood levels of radioantibodies?

Conclusion

The use of a second antibody significantly reduced blood levels of radioantibodies and improved tumor-blood ratios, although it also decreased the amount of antibody at the tumor site.

Supporting Evidence

  • Administration of the second antibody produced up to a tenfold reduction in blood levels of radioantibodies.
  • Despite reduced antibody levels at the tumor site, tumor-blood ratios remained superior to the control group.
  • Estimated dosimetry showed lower total doses to normal tissues with the use of the second antibody.

Takeaway

This study found that giving a second antibody can help clear radioactive antibodies from the blood, making treatment safer and potentially more effective.

Methodology

Mice with human colorectal tumor xenografts were injected with yttrium-90-labelled antibodies and then given a second antibody at various time points to assess clearance and tumor-blood ratios.

Potential Biases

Potential bias in the selection of time points for administering the second antibody and measuring outcomes.

Limitations

The study primarily focused on short-term effects and did not evaluate long-term outcomes or potential side effects in humans.

Participant Demographics

Nude mice bearing human colorectal tumor xenografts.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication